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Introduction S100A7 (psoriasin) is present within the epidermal differentiation complex on 1q21 chromosome and was initially identified in the skin of patients suffering from psoriasis, a hyperproliferative skin disease characterized by abnormal differentiation (1, 2) . In addition, increased S100A7 expression has been reported in nearly all types of SCC tissues as well as adenocarcinomas of the breast (3) (4) (5) (6) (7) . Our recent works uncovered that the S100A7 acted as a dual regulator in promoting proliferation and suppressing differentiation in several SCC cells (8) (9) (10) (11) . S100A7 has also been shown attributes to resistance of anoikis result in tumor growth by activating several signaling pathways (12, 13) . Interestingly, S100A7 has been induced by cytokines, cell dense and suspension culture, and by activation of the Hippo pathway (8, 9) .
The Hippo pathway, initially discovered in Drosophila, is an evolutionarily conserved and potent regulator of cell growth and apoptosis (14) . Core components of the Hippo pathway include a kinase cascade of MST1/2 and LATS1/2. YAP (Yes-associated protein), as a transcription coactivator, is the ultimate effector of the Hippo pathway (15) (16) (17) . In response to stimulation, LATS1/2 phosphorylate YAP at Serine 127 and confine it to the cytoplasm, where it can no longer binding with TEAD (TEA domain) to promote or repress YAP-dependent target genes as YAP in nucleus (14) . Recent advances have rapidly expanded the understanding of YAP acts as an oncogene in variety types of cancers (18) . For example, YAP has been identified as a candidate oncogene in human chromosome 11q22 amplicon (19) p63 is composed of multiple isoforms with overlapping and unique activities. The p63 isoforms can be placed into two groups: the transactivation domain isoforms (TAp63), which structurally resemble p53 and acts as tumor suppressors; and the ΔN isoforms (ΔNp63), which bind to p53, TAp63 and TAp73 and inhibit their function, thus acting as oncogenes (22-24). Unlike ΔNp63, TAp63 is not expressed or is present at low levels in a variety of cancers (25, 26) . Recent studies been reported that NF-B can suppress p63 expression through the direct interaction of p65 with the proximal region of the p63 promoter (26) . In contrast, expression of IκB-α results in strong induction of p63 expression, indicating that p63 is, indeed, negatively regulated by NF-κB (27, 28) . In addition, some cross-talk between p63 and the Hippo pathway has been discovered recently (25, 29) , for example, ΔNp63 directly interacts with the Hippo effector YAP and is a mediator of YAP function in the epithelium of lung airways (30) . p63 co-amplified with ACTL6A in SCC to drive YAP activity, which resulted in regeneration, proliferation and poor prognosis (31) .
Our recent studies uncover that S100A7 induction is repressed by YAP via the Hippo pathway in several SCC cells (10) (11) (12) . Although S100A7 expression is negatively regulated by nuclear YAP, both S100A7 and YAP perform the similar functions in promoting cells proliferation and inhibiting squamous differentiation (8) (9) (10) . In this report, we provide evidence that S100A7 also inhibits YAP expression and activity through p65/NF-κB-mediated repression of ΔNp63, and S100A7 represses drug-induced apoptosis via inhibiting of YAP.
Materials and Methods

Cell lines
Human carcinoma cell lines HCC94, A431, and FaDu were purchased from the Chinese Academy of Sciences Committee Type Culture Collection Cell Bank and were authenticated by short tandem repeat analysis at HK Gene Science Technology Co. (Beijing, China). The cells were cultured in 1640 containing 10% fetal calf serum (FCS), penicillin (100 units/mL), streptomycin (100 units/mL), and 2 mmol/L glutamine and grown at 37℃ in a humidified atmosphere with 5% CO 2 .
Plasmids
For pCMV14-Flag-ΔNp63, the ΔNp63 cDNA fragment was amplified using 5'-AGATATCATGTTGTACCTGGAAAACAATGCCC-3'and 5'-ATCTAGACTCCCCCTCCTCTTTGATGCGC-3', and then was cloned into the mammalian expression vector pCMV14 (Invitrogen, Carlsbad, CA, USA) using EcoR5 and XbaI restriction enzymes (Takara).
siRNA and transfection
To silence the expression of S100A7, MST1, LATS1, YAP and ΔNp63, all siRNAs as Table S1 ).
Drug treatment
DDP (Qilu pharmaceutical limited company, 5050221DB) and VP-16 (Jiangsu Hengrui pharmaceutical Limited by Share Ltd, 15101538) were used as indicated.
The specific inhibitor Caffeic acid phenethyl ester (CAPE) (SIGMA, C8221-1G) was used to inhibit NF-KB signaling pathway in cells.
Reverse transcription and quantitative RT-PCR
Total RNA was extracted from cells for the generation of single-stranded cDNA.
Quantitative RT-PCR (qPCR) was performed using an ABI 7300 Real-time PCR System (Applied Biosystems) with the Power SYBR Green PCR Master Mix (Applied Biosystems) in a final volume of 20 μL. GAPDH was used as an endogenous control for each sample. The primers used for each of the genes are listed (Supplementary Table 2 ).
Western blot
Western blotting analysis was performed as previously described (11) . The following antibodies were used: S100A7 (1/1000; Abcam, ab13680); YAP (1/500, Santa Cruz, sc-101199); pYAP (S127) (1/1000; Cell Signaling Technology, 13008S); MST anti-Flag tag (CWBIO, CW0287A); anti-His tag (MBL, D291-3); GAPDH (1/4000; ZSGB-BIO, TA-08) and β-actin (1/4000; ZSGB-BIO, TA-09) were used as loading controls.
Immunofluorescence staining
Immunofluorescence staining analysis was performed as previously described (11) . To examine the expression pattern of S100A7, ΔNp63 and YAP in cells, cells were plated on coverslips and then cultured for 24 h before handled. Cells were fixed with 3.4% paraformaldehyde for 20 min and then permeabilized with 0.5% PBS-Triton X-100.
After blocking in 3% PBS-BSA for 30 min, slides were incubated with anti-S100A7 (Abcam), anti-ΔNp63 (Biolegend) or anti-YAP (Cell Signaling Technology) for 1 h at 37℃, antibodies diluted in 1% BSA. After washing with PBS, slides were incubated with goat anti-mouse TRTIC (tetramethyl thodamine isothiocyanate) 555-(ZSGB-BIO, ZF-0316) or goat anti-Rabbit FITC (fluorescein isothicocyanate) 488-(ZSGB-BIO, ZF-0312) conjugated secondary antibodies for 1 h at 37℃. The nuclei were stained using DAPI (4', 6-diamidino-2-phenylindole). The targeted proteins were detected using confocal microscopy (ZEISS LSM700, Germany) and a ZEISS LSM700 laser-scanning confocal microcope image system. Immnohistochemistry was performed as described in our previous study (11) .
Immunohistochemistry
Anti-S100A7 (1/200), anti-ΔNp63 (1/100) and anti-pYAP-S127 (1/200) were separately incubated with the specimens. The goat anti-Rabbit/Mouse secondary antibody was purchased from MAIXINBIO (KIT-5010). S100A7, ΔNp63 and pYAP-S127 expression was detected using a fluorescence microscope (ZEISS ImagerA1, Germany).
High content live cell imaging systems
S100A7 promote p65 nuclear translocation was detected by high content live cell imaging system. Cells were seeded in the cover glass, fixed after 24h, and permeabilized as for the cell immunostaining. The cells were then blocked with 3% BSA-PBS solution. P65 antibody was applied for 1h at 37°C followed by washing and subsequent incubation with FITC-labeled goat anti-rabbit IgG for 1h at 37°C.
Finally, the nuclei were stained using Hoechst 33342 for 10 min at room temperature.
High content live cell imaging systems was applied to detect the p65 nuclear translocation, and 'translocation enhanced' analytical model was used to given translocation rate.
Cell apoptosis analysis
Apoptosis was measured by flow cytometry. 5-GCCCTACCACACCAAGTGATA-3(forward), and
5-AGCAAGGAAAAAGTCCGTG-3(reverse) (29).
Statistical analysis
All of the experiments were repeated at least twice. Statistical analysis was performed using GraphPad Prism software. The statistical significance was evaluated using Student's t-test (2-tailed) to compare two groups of data. The asterisks indicate significant differences between the experimental groups and corresponding control condition. Differences were considered statistically significant at a P-value of less than 0.05. P-values <0.05, <0.01, <0.001, <0.0001 are indicated with one, two, three, and four asterisks, respectively. Our previous research revealed that YAP acted as a suppressor on S100A7 induction in several SCC cells. Considering S100A7 and YAP perform some similar functions in promoting cells proliferation and inhibiting squamous differentiation, we wonder whether S100A7 also in return regulates YAP expression or activity? To test our hypothesis, we performed stably overexpression of S100A7 in A431 cells (S100A7-overexpressed A431 cells) which expressed low level of S100A7. As expected, S100A7 overexpression significantly inhibited the expression of YAP and also resulted in activation of the Hippo pathway which was indicated by increased in LATS1-T1079 (LATS1-HM) and YAP-S127 phosphorylation (Fig. 1A) . On the contrary, depletion of S100A7 in HCC94 cells which expressed high level of S100A7 strikingly improved YAP expression and inhibited the Hippo pathway (Fig. 1B) .
Results
S100A7 represses YAP expression and its activity
Using quantitative RT-PCR (qPCR), we also analyzed the expression of CTGF (Connective tissue growth factor) and/or CYR61 (Cysteine-rich angiogenic inducer 61), two direct endogenous markers of YAP activity. Indeed, CYR61 transcription had a significant reduction in S100A7-overexpressed A431 cells (Fig. 1C) , whereas CYR61 and CTGF expressions were extremely increased after knockdown of S100A7 in HCC94 cells (Fig. 1D) . Importantly, the similar results were also obtained in S100A7-silenced FaDu cells ( Supplementary Fig. 1A 
S100A7 suppresses YAP expression and activity via repression of ΔNp63
As S100A7 is neither a transcription factor nor a phosphokinase, we speculate that S100A7 is impossible to regulate YAP expression and its phosphorylation directly. A more recent study showed that ΔNp63 could directly regulate YAP expression through binds the YAP promoter (29) . Therefore, we speculated that S100A7 repressed YAP expression and its activity through inhibition of ΔNp63. To test our hypothesis, we examined the expression of ΔNp63 in S100A7-overexpressed A431 cells and S100A7-silenced HCC94 cells by western blot. As expected, S100A7 overexpression obviously inhibited ΔNp63 expression in A431 cells (Fig. 2A) . The opposite result was also observed in S100A7-silenced HCC94 cells (Fig. 2B) . Interestingly, TAp63
was nearly undetectable in all tested cells (Supplementary Fig. 2A) , and TAp63 has no regulatory effect on YAP expression and activity (Data not shown). Next, to confirm the regulatory effect of ΔNp63 on YAP expression and its activity, we silenced ΔNp63 using p63 siRNA in A431 and HCC94 cells. Indeed, knockdown of ΔNp63 markedly repressed YAP expression and activity which was reflected by a decrease of YAP protein levels and a great increase of YAP phosphorylation in A431 (Fig. 2C ) and HCC94 cells (Fig. 2D) . We also noted that CYR61 and CTGT have a great decrease after ΔNp63 knockdown ( Fig. 2E and F) . Similar results were also observed in FaDu cells ( Supplementary Fig. 2B and C knockdown of ΔNp63 significantly decreased YAP expression and its nuclear accumulation in both A431 and HCC94 cells ( Fig. 2G and H) . To confirm whether S100A7 could influenced the promote effect of ΔNp63 on YAP expression and YAP activity, we transfected ΔNp63 plasmid into S100A7-overexpressed A431 and the corresponding control cells. As anticipated, overexpression of ΔNp63 almost entirely recovered the expression of total YAP and the level of pYAP-S127 in S100A7-ovexexpressed A431 cells compared with the control cells (Fig. 3A) .
Similarly, in HCC94 cells, the total YAP was decreased and pYAP-S127 was increased in double deletion of S100A7 and ΔNp63 compared with single silencing of S100A7 (Fig. 3B) . In fact, both the total YAP expression and its activity nearly reached the levels of the control cells. Finally, to validate the correlation of these three proteins in vivo, three consecutive sections of skin SCC tissues microarrays were stained by specific S100A7, ΔNp63 and pYAP-S127 antibodies, respectively. Consistent with our observation in vitro, S100A7 presented the similar expression pattern with pYAP-S127, whereas both proteins were negatively correlated with ΔNp63 staining (Fig. 3C) . In S100A7 high expression skin SCC tissues, ΔNp63 don't express (Fig. 3C, H black arrow) , or low expressed in S100A7 relatively weak areas (Fig. 3C , H white arrow). ΔNp63 generally high expressed in skin SCC tissues with S100A7 low expression or non-expression (Fig. 3C, L) . These data in vitro and in vivo directly or indirectly support that the ability of S100A7 represses YAP expression and activity is likely to be dependent on ΔNp63. 
As p63 is negatively regulated by NF-κB pathway in both skin cancers and stratified epithelial cells and Rel/p65 can also repress ΔNp63 expression in a transcription-dependent in epithelial cells (26) (27) (28) , we examined the activity of NF-B and its target genes expressions (cox-2 and survivine) in S100A7 overexpressed A431 cells. Efficient S100A7 over-expression greatly enhanced the phosphorylation of IKKα/β, IB, p65 (Fig. 4A ) and the transcription of cox-2 and survivine (Fig. 4B) . To further confirm the subcellular location of p65, we extracted the whole cell protein and nucleoprotein from the S100A7-overexpressed and the control cells and examined the protein level of p65 by western blot. The data showed that over-expression of S100A7 really improved p65 nuclear translocation (Fig. 4C) . The quantitative observation of nuclear p65 was performed in A431 cells by high-throughput microscopy (Fig. 4D ). The percentage of nuclear p65 staining was 23.8015% and 10.1944% in S100A7-overexpressed A431 cells and the control cells, respectively (Fig. 4E) . CAPE is a specific inhibitor of NF-κB (32) . To further confirm these results, we treated S100A7-overexpressed cells and the control cells with or without CAPE.
The results shown that CAPE treatment obviously counteract the inhibitory effect of S100A7 on the expression of ΔNp63, keratin5/14 (two target genes of ΔNp63) (Fig.   4F ). Collectively, our results fully illustrated that S100A7 inhibits the expression of ΔNp63 via activating of the NF-κB signaling pathway.
ΔNp63 inhibits the Hippo pathway and directly regulates YAP expression
In order to investigate how ΔNp63 regulated YAP expression and activity, we silenced 
ΔNp63 in A431 and HCC94 cells using p63 siRNA and detected the Hippo pathway.
We found that knockdown of ΔNp63 moderately increased MST1 expression and LATS1-HM phosphorylation in both A431 and HCC94 cells (Fig. 5A) , whereas ΔNp63 over-expressing in the same cells appeared the opposite phenomenon (Fig.   5B) . Strikingly, the finding that ΔNp63 decreased MST1 expression led us to hypothesize that ΔNp63, as a nuclear transcription factor, likely repressed MST1 expression which resulted in inhibition of the Hippo pathway and YAP phosphorylation. To assess this hypothesis, we examined the transcription level of LKB1 (a kinase of MST1), MST1 and LATS1 in the cells after silencing of ΔNp63.
The result showed that MST1 mRNA level was significantly up-regulated in the absence of ΔNp63, whereas LKB1 and LATS1 had no change when compared with the control cells (Fig. 5C) . Besides, transient silencing of MST1 impaired the increased in YAP phosphorylation by S100A7 overexpression in A431 cells (Fig. 5D ). In addition, the finding that ΔNp63 could directly bind to the region of YAP promoter by chromatin immunoprecipitation (ChIP) provided the support for direct transcriptional induction of YAP expression by ΔNp63 (Fig. 5E) . Together, these results strongly support that ΔNp63 increases YAP activity through inhibition of the Hippo pathway that is mediated by repression of MST1 expression and promotes YAP expression through its directly binding with YAP promoter.
S100A7 represses chemotherapy-induced apoptosis via inhibiting of YAP
Except for its controlling of cell growth in physiological condition, YAP also plays an Considering the relationship of S100A7 and YAP, we hypothesize that both YAP and S100A7 may be involved in the regulation of chemosensitivity in our tested cells. To substantiate this possibility, A431 and HCC94 cells were treated with DDP and VP16 to induce apoptosis. Interestingly, stably expressed S100A7 in A431 cells had a significant inhibiting effect on drugs-induced apoptosis. Conversely, overexpression YAP promoted apoptosis but this effect could be rescued by overexpression of S100A7 in A431 cells, suggesting that S100A7 effectively overcame apoptotic induction by YAP (Fig. 6A-D) . Consistently, the DDP/VP16-induced apoptosis in HCC94 cells was significantly promoted by single removal of S100A7 or overexpression of YAP, and an obviously improvement of apoptosis was observed by both combinations (Fig. 6E-H) . Further, corresponding PARP cleavage was also examined by Western blotting. The results demonstrated that the detectable PARP cleavage only occurred in A431 and HCC94 cells treated with both drugs. Consistent with the percentage of apoptosis, overexpression of S100A7 resisted DDP-and VP16-induced PARP cleavage in A431 cells, whereas overexpression of YAP significantly promoted PARP cleavage. S100A7 also has a significant inhibiting effect on YAP induced PARP cleavage (Fig. 6I-L) . The similar effects of S100A7 and YAP on PARP cleavage were also observed in HCC94 cells treated with DDP and VP16
( Fig. 6M-P) . Together, these data strongly suggest that both S100A7 and YAP regulate the chemosensitivity of A431 and HCC94 cells, but they perform the opposite effects. In this study, we have demonstrated that S100A7 activates the Hippo pathway through NF-B signaling pathway, and resists chemotherapy-induced apoptosis in SCC cells.
On the basis for our results, we have proposed a working model for S100A7 function, which is summarized in Fig. 7 . In this model, First, S100A7 attenuated YAP activity through NF-B/p65-Np63-mediated activation of the Hippo pathway. Second, S100A7 suppressed YAP expression through NF-B/p65-mediated repression of Np63. The supporting data showing that overexpression of S100A7 in A431 cells could activate NF-B signaling pathway which resulted in the translocation of p65 into the nucleus, and then the nuclear p65 suppressed Np63 expression. After that, downregulation of Np63 induced MST1 expression. Finally, YAP activity was suppressed by activation of the Hippo pathway via upregulation of MST1 expression.
Conversely, silencing of S100A7 in HCC94 cells could increase NP63 expression which resulted in an increase of YAP expression and its activity. After that, p63 positively regulated YAP expression through its ability to directly bind the promoter of YAP. Therefore, we conclude that S100A7 represses both YAP expression and its activity. Although accumulating evidence suggests that MST1/2 are not absolutely required for the regulation of YAP under various conditions (14) , our results demonstrate that MST is critical for S100A7-activated the Hippo pathway in the tested cancer cells. regulates genes that result in basal cell proliferation (34, 35) . Forced expression of ΔNp63 is sufficient to drive stem-like proliferation and tumorigenesis in primary keratinocyte (36) . Hence, ΔNp63 is considered as an oncogene and overexpression of ΔNp63 is a hallmark of SCCs (37) . In the present study, we found that overexpression of S100A7 could activate IKK/, the key regulatory step in NF-B pathway and increased in p65 phosphorylation at Ser536 and its nuclear localization. We further confirmed that S100A7 overexpression significantly decreased the expression of NP63 but increased the expressions of cox-2 and survivine in A431 cells. Conversely, silencing of S100A7 promoted Np63 expression in HCC94 cells. As NIK (NF-κB-inducing kinase) can phosphorylate and activate IKKα and IKKβ and is also regulated by MAPK/Erk cascade (38, 39), we speculate that the effect of S100A7 on NF-B pathway is likely through regulation of NIK or MAPK/Erk activity in the cells.
In addition, we also treat S100A7-overexpressed A431 cells and the control cells with or without CAPE (an inhibitor of NF-B). The results revealed that overexpression of S100A7 significantly inhibited the expressions of ΔNp63 and keratin 5/14; whereas CAPE treatment obviously counteracted the inhibitory effect of S100A7 on the above-mentioned gene expressions. These findings further illustrated that S100A7 Therefore, upstream regulators of the Hippo pathway are being unveiled. In our present study, we demonstrate that S100A7 not only promotes LATS1 kinase activity but suppresses YAP expression, strongly supporting that S100A7 is a new upstream regulator of the Hippo pathway. Additionally, based on the new definition of the Hippo pathway, proteins that specifically influence LATS1 kinase activity and the functional output of YAP/TAZ should be considered as 'Hippo pathway' components (46), our results also suggest that S100A7 is also considered as a new member of the Hippo pathway components. Interestingly, our previous study uncovered that S100A7 induction was also repressed by YAP through activation of the Hippo pathway in A431, HCC94 and FaDu cells under suspend and dense culture or F-actin disruption (8, 9) . Combined with the findings in the present study, we conclude that there is a negative correlation of 
S100A7 and YAP, and reciprocal negative regulation between the two proteins in SCC cells, at least in A431, HCC94 and FaDu cells. To investigate the functions of S100A7 and YAP in SCC cells, we found that S100A7 and YAP have the similar or opposite functions in the above-mentioned cells. First, overexpression of S100A7 in A431 cells promoted cells proliferation and inhibited differentiation, whereas the opposite results was obtained in silencing of S100A7 in HCC94 cells (11) . Similarly, knockdown of YAP in all these three cells resulted in a decrease of cells growth (8, 9) . Second, either inhibition or activation of chemotherapy-induced apoptosis was observed in S100A7-overexpressed cells or S100A7-silenced cells, suggesting that S100A7 expression reduced the chemosensitivity in these cells. 
